Conferences
IBCN 2024: Oncolytic Virotherapy Expressing a Novel TLR Agonist and IL-15 for the Treatment of NMIBC
September 21, 2024
IBCN 2024: Spatial Proteomics and Transcriptomics Reveal an Altered Immune Cell Landscape in Bladder Cancer Patients Unresponsive to BCG Treatment
September 21, 2024
IBCN 2024: Molecular Subtypes and Outcomes in the VESPER Trial
September 21, 2024
IBCN 2024: Molecular Subtyping in 2024: The LUMBER-NAC Trial
September 21, 2024
IBCN 2024: GUSTO Trial
September 21, 2024
IBCN 2024: ADC Toxicity, Management and Clinical Trial Updates
September 21, 2024
IBCN 2024: Benefit of Whole-Pelvis Radiation for Patients with Muscle Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis
September 21, 2024
IBCN 2024: Influence of Immortal Time Bias and Conditional Survival on the Comparison of Radical Cystectomy Versus Trimodality Therapy for Muscle Invasive Bladder Cancer
September 21, 2024
IBCN 2024: Augmented Cystoscopy with Deep Learning
September 21, 2024
IBCN 2024: The Value of mpMRI to Assist in Decision Making in Muscle Invasive Bladder Cancer
September 21, 2024
IBCN 2024: TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Patients with BCG Unresponsive High-Risk NMIBC: Results from SunRISe-1
September 21, 2024
IBCN 2024: AI in Bladder Cancer: The Good, the Bad, and the Ugly
September 21, 2024
IBCN 2024: AI-Enabled Bladder Cancer Grading: Externally Validating Quantitative Nuclear Features and Demonstrating Their Potential to Better Predict Time to Recurrence
September 20, 2024